Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Docetaxel, Carboplatin, Trastuzumab and Bevacizumab (TCH+B) For Early-Stage HER-2/Neu(+) Breast Cancer and Bone Marrow Micrometastases

NCT00949247 is registered in ClinicalTrials.gov with Case Comprehensive Cancer Center as lead sponsor.

NCT NCT00949247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00949247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Docetaxel, Carboplatin, Trastuzumab and Bevacizumab (TCH+B) For Early-Stage HER-2/Neu(+) Breast Cancer and Bone Marrow Micrometastases
Lead sponsor
Case Comprehensive Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2009
Completion date
January 31, 2013
Enrollment
20 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer